Mundipharma enter strategic collaboration to co-develop FOLOTYN Allos Therapeutics.

Under the agreement, Allos retains full commercialization privileges for FOLOTYN in the usa and Canada, with Mundipharma having unique rights to commercialize FOLOTYN in every other countries. Allos is going after regulatory approval to advertise FOLOTYN in the European Union for relapsed or refractory PTCL. Allos’ Marketing Authorisation Application was recognized for review by the European Medicines Company in December 2010. Under the collaboration, Allos will receive an upfront payment of $50 million and potential regulatory and commercial progress – and sales-dependent milestone payments of up to $310.5 million. Allos is also entitled to receive tiered double-digit royalties based on net sales of FOLOTYN within Mundipharma’s licensed territories.The surgeries had shown to be a success, until lately when he began to develop serious heart-rhythm irregularities and a big blood clot in his heart. David Morales, chief of cardiothoracic surgery. This kind of pre-planning has an enormous impact on patient care and recovery. Working with 3D printing technology since 2006, the lab team has generated various prototypes for applications which range from the CEAS Medical Gadget Innovation and Entrepreneurship Plan and aerospace research to university research and combustion study.